Lilly’s Older Drugs Face More Price Pressure Than Newer Ones

Eli Lilly & Co.’s older drugs are more prone to price pressure than its newest ones, a company executive said Friday on a call with investors.

Drugmakers face raised scrutiny from patients, health insurers and politicians over the high cost of prescription medicine. Yet Indianapolis-based Lilly’s comments make clear that its customers are willing to pay up for the most innovative treatments even as the industry faces pushback on price increases on older therapies.